Zygolide brings first FDA-approved generic pergolide for PPID

Zygolide, Dechra’s generic pergolide tablet for horses with pituitary pars intermedia dysfunction, or PPID, entered the U.S. market after FDA approval in late 2025, giving veterinarians and pet parents a new prescription option alongside branded Prascend. FDA said Zygolide is the first generic pergolide tablet approved for control of clinical signs associated with equine Cushing’s disease and determined it is bioequivalent to Prascend, which was first approved in 2011. Product materials highlighted in The Horse promotion emphasize practical features aimed at day-to-day adherence, including a peppermint-flavored 1 mg tablet and a half-scored format for dose adjustment, while the campaign also leans into owner-facing quality-of-life messaging such as “Rediscover the partnership with Zyoglide” and “Help your horse feel their best,” alongside explicit cost-effectiveness claims. (fda.gov)

Why it matters: For equine practitioners, the significance is less about a new mechanism and more about access, administration, and cost conversations. FDA’s approval pathway confirms Zygolide as a generic equivalent rather than a novel therapy, but that still matters in a chronic disease that often requires lifelong daily treatment and periodic dose adjustment. The FDA freedom of information summary lists a starting dose of 2 mcg/kg once daily, adjustable up to 4 mcg/kg daily, and notes the product is supplied in 60- and 160-tablet cartons. Safety information also remains familiar to clinicians using pergolide, including anorexia, lethargy, weight loss, diarrhea, colic, and the need to avoid crushing tablets because of human exposure risk. The added owner-directed messaging around partnership, happy moments, and affordability suggests Dechra is trying to support adherence not just with formulation features but with emotional and budget framing too. (animaldrugsatfda.fda.gov)

What to watch: Watch for how quickly Zygolide gains distribution, whether it meaningfully changes pricing at the clinic and pharmacy level, and how veterinarians position it in adherence and long-term PPID management discussions. Dechra’s promotional language is already testing a mix of practical and emotional appeals, so it will be worth seeing whether “cost-effective treatment” and partnership-focused messaging resonate with horse owners managing chronic PPID care. (scahealth.com)